FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3015949565> ?p ?o ?g. }

• W3015949565 endingPage "492" @default.
• W3015949565 startingPage "485" @default.
• W3015949565 abstract "Background Drug-eluting stents with biodegradable polymers have been designed to improve safety and efficacy. However, drug-eluting stents with biodegradable polymers may not be a class effect, as stent strut thickness, polymer coating, and drug resorption differ between these groups of stents. Twelve months results of Scandinavian Organization for Randomized Trials With Clinical Outcome VII showed that ultrathin-strut sirolimus-eluting Orsiro stent was noninferior to the biolimus-eluting Nobori stent. The sirolimus-eluting Orsiro stent was associated with a reduced risk of definite stent thrombosis. Methods The Scandinavian Organization for Randomized Trials With Clinical Outcome VII trial is a prospective multicenter randomized clinical trial comparing sirolimus-eluting Orsiro stent and biolimus-eluting Nobori stent in all-comers patients. The endpoint target lesion failure was a composite of cardiac death, myocardial infarction (not related to other than index lesion) and target lesion revascularization. Results A total of 1261 patients were randomized to treatment with sirolimus-eluting Orsiro stent and 1264 patients to biolimus-eluting Nobori stent and followed for 3 years. At 3-year the target lesion failure was comparable for sirolimus-eluting Orsiro stent (9.0%) and the biolimus-eluting Nobori stent (9.1%), (rate ratio, 0.99; 95% confidence interval, 0.77–1.29). Cardiac death (sirolimus-eluting Orsiro stent 3.0% vs. biolimus-eluting Nobori stent 2.6% [rate ratio, 1.16; 95% confidence interval, 0.73–1.86]), target lesion revascularization (sirolimus-eluting Orsiro stent 5.2% vs. biolimus-eluting Nobori stent 5.9% [rate ratio, 0.90; 95% confidence interval, 0.64–1.25]), myocardial infarction (sirolimus-eluting Orsiro stent 4.7% vs. biolimus-eluting Nobori stent 4.5% [rate ratio, 1.04; 95% confidence interval, 0.72–1.50]), and definite stent thrombosis (sirolimus-eluting Orsiro stent 1.0% vs. biolimus-eluting Nobori stent 1.7% [rate ratio, 0.59; 95% confidence interval, 0.30–1.18]) did not differ significantly between the two groups. Conclusion At 3-year follow-up, target lesion failure did not differ among ultrathin-strut sirolimus-eluting Orsiro stent and biolimus-eluting Nobori stent with biodegradable polymers." @default.
• W3015949565 created "2020-04-17" @default.
• W3015949565 creator A5002757728 @default.
• W3015949565 creator A5004368211 @default.
• W3015949565 creator A5004894475 @default.
• W3015949565 creator A5006509100 @default.
• W3015949565 creator A5007579304 @default.
• W3015949565 creator A5013878625 @default.
• W3015949565 creator A5019514522 @default.
• W3015949565 creator A5053274857 @default.
• W3015949565 creator A5060335933 @default.
• W3015949565 creator A5068286823 @default.
• W3015949565 creator A5073782609 @default.
• W3015949565 date "2020-03-20" @default.
• W3015949565 modified "2023-10-16" @default.
• W3015949565 title "Clinical outcomes three-year after revascularization with biodegradable polymer stents: ultrathin-strut sirolimus-eluting stent versus biolimus-eluting stent: from the Scandinavian organization for randomized trials with clinical outcome VII trial" @default.
• W3015949565 cites W1032315853 @default.
• W3015949565 cites W1511423923 @default.
• W3015949565 cites W1527614413 @default.
• W3015949565 cites W1997760014 @default.
• W3015949565 cites W2000590814 @default.
• W3015949565 cites W2009328296 @default.
• W3015949565 cites W2056348491 @default.
• W3015949565 cites W2066501580 @default.
• W3015949565 cites W2073481148 @default.
• W3015949565 cites W2083630382 @default.
• W3015949565 cites W2087150869 @default.
• W3015949565 cites W2119470649 @default.
• W3015949565 cites W2124385743 @default.
• W3015949565 cites W2154190679 @default.
• W3015949565 cites W2154567759 @default.
• W3015949565 cites W2156613502 @default.
• W3015949565 cites W2159380001 @default.
• W3015949565 cites W2170026686 @default.
• W3015949565 cites W2409398270 @default.
• W3015949565 cites W2547759268 @default.
• W3015949565 cites W2612654136 @default.
• W3015949565 cites W2620950555 @default.
• W3015949565 cites W2771764789 @default.
• W3015949565 cites W2810314526 @default.
• W3015949565 cites W2888902549 @default.
• W3015949565 cites W2889776551 @default.
• W3015949565 doi "https://doi.org/10.1097/mca.0000000000000875" @default.
• W3015949565 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32271243" @default.
• W3015949565 hasPublicationYear "2020" @default.
• W3015949565 type Work @default.
• W3015949565 sameAs 3015949565 @default.
• W3015949565 citedByCount "8" @default.
• W3015949565 countsByYear W30159495652020 @default.
• W3015949565 countsByYear W30159495652021 @default.
• W3015949565 countsByYear W30159495652022 @default.
• W3015949565 crossrefType "journal-article" @default.
• W3015949565 hasAuthorship W3015949565A5002757728 @default.
• W3015949565 hasAuthorship W3015949565A5004368211 @default.
• W3015949565 hasAuthorship W3015949565A5004894475 @default.
• W3015949565 hasAuthorship W3015949565A5006509100 @default.
• W3015949565 hasAuthorship W3015949565A5007579304 @default.
• W3015949565 hasAuthorship W3015949565A5013878625 @default.
• W3015949565 hasAuthorship W3015949565A5019514522 @default.
• W3015949565 hasAuthorship W3015949565A5053274857 @default.
• W3015949565 hasAuthorship W3015949565A5060335933 @default.
• W3015949565 hasAuthorship W3015949565A5068286823 @default.
• W3015949565 hasAuthorship W3015949565A5073782609 @default.
• W3015949565 hasConcept C126322002 @default.
• W3015949565 hasConcept C141071460 @default.
• W3015949565 hasConcept C164705383 @default.
• W3015949565 hasConcept C168563851 @default.
• W3015949565 hasConcept C2777546689 @default.
• W3015949565 hasConcept C2777921159 @default.
• W3015949565 hasConcept C2778283817 @default.
• W3015949565 hasConcept C2778583881 @default.
• W3015949565 hasConcept C2780400711 @default.
• W3015949565 hasConcept C2781464078 @default.
• W3015949565 hasConcept C500558357 @default.
• W3015949565 hasConcept C71924100 @default.
• W3015949565 hasConceptScore W3015949565C126322002 @default.
• W3015949565 hasConceptScore W3015949565C141071460 @default.
• W3015949565 hasConceptScore W3015949565C164705383 @default.
• W3015949565 hasConceptScore W3015949565C168563851 @default.
• W3015949565 hasConceptScore W3015949565C2777546689 @default.
• W3015949565 hasConceptScore W3015949565C2777921159 @default.
• W3015949565 hasConceptScore W3015949565C2778283817 @default.
• W3015949565 hasConceptScore W3015949565C2778583881 @default.
• W3015949565 hasConceptScore W3015949565C2780400711 @default.
• W3015949565 hasConceptScore W3015949565C2781464078 @default.
• W3015949565 hasConceptScore W3015949565C500558357 @default.
• W3015949565 hasConceptScore W3015949565C71924100 @default.
• W3015949565 hasIssue "6" @default.
• W3015949565 hasLocation W30159495651 @default.
• W3015949565 hasOpenAccess W3015949565 @default.
• W3015949565 hasPrimaryLocation W30159495651 @default.
• W3015949565 hasRelatedWork W2045160638 @default.
• W3015949565 hasRelatedWork W2121972315 @default.
• W3015949565 hasRelatedWork W2747702104 @default.
• W3015949565 hasRelatedWork W2781492264 @default.
• W3015949565 hasRelatedWork W2810386253 @default.
• W3015949565 hasRelatedWork W2905507539 @default.
• W3015949565 hasRelatedWork W2994117025 @default.

• next